FinVector is a cGMP manufacturer specialising in viral-based gene therapy products. With over 30 years of expertise in drug discovery and manufacturing, the company aims to improve the lives of patients, particularly those battling chronic conditions like bladder cancer.

Based in Finland, FinVector combines cutting-edge science and technology to develop gene therapies, focusing on both innovation and quality in manufacturing. Their state-of-the-art facilities are designed to meet the demands of modern therapeutic development, ensuring the delivery of safe, effective treatments.

Key Products and Services

• Viral-based gene therapies for chronic diseases
• cGMP manufacturing services
• Drug discovery and development expertise
• State-of-the-art gene therapy production facilities

FinVector remains at the forefront of gene therapy, driving advancements in healthcare innovation and offering comprehensive services to support global therapeutic initiatives.